| Name | Title | Contact Details |
|---|
Parkland is a diverse community of 30,000, and the City provides a variety of services for these citizens. Learn more about what Parkland has to offer you and your family! Parkland is a tranquil city nestled in a serene, wooded environment in Northwest...
Fairfield Medical Center is a Lancaster, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fresenius Medical Care North America (FMCNA) is the premier health care company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country`s largest practice of hospitalist and post-acute providers, Fresenius Medical Care provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world`s only fully vertically integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Centennial House is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.